7153b1ef-41b9-4b43-a766-0910291502dd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- MTORC1_SIGNALING+0.200
- PROTEIN_SECRETION+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- ANDROGEN_RESPONSE+0.100
- ANGIOGENESIS+0.100
- ESTROGEN_RESPONSE_LATE+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- HEDGEHOG_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- TGF_BETA_SIGNALING-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- APOPTOSIS-0.200
- COAGULATION-0.200
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG592 | — | — | 0.869 |
| 2 | SRR1516044 | — | — | 0.863 |
| 3 | MBCProject_6109_T1B_RNA | — | B | 0.858 |
| 4 | TCGA-4Z-AA84-01A-11R-A39I-07 | — | — | 0.855 |
| 5 | SRR8518345 | — | E | 0.852 |
| 6 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.848 |
| 7 | MNG332 | — | — | 0.845 |
| 8 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.844 |
| 9 | X7c81e3d9.c538.468a.8a2a.f34513bac230 | — | cohortA3 | 0.844 |
| 10 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |